|
**Overview**: Infertility Comprehensive Female Panel**Introduction**: The Infertility Comprehensive Female Panel is a diagnostic tool designed to assess female infertility causes using serum samples. In India, infertility affects ~15-20 percent of couples (~27-30 million couples), with female factors contributing to ~40-50 percent of cases (PCOS, diminished ovarian reserve, tubal blockage, endometriosis). High morbidity from under-testing in rural/low-SES women with primary/secondary infertility, limited endocrine labs, delayed diagnosis leading to prolonged emotional/financial burden, social stigma, or missed IVF opportunity. Per endocrinology practices aligned with ICMR, FOGSI, and Indian Society for Assisted Reproduction guidelines, the test employs immunoassay for FSH, LH, prolactin, AMH, estradiol, progesterone, and TSH over 1-2 days with high accuracy, valuable for evaluating ovulatory dysfunction, ovarian reserve, hyperprolactinemia, and thyroid-related infertility. This diagnostic falls under reproductive screening and targets women with irregular cycles, anovulation, or failed conception >1 year, addressing accurate detection to guide clomiphene, letrozole, gonadotropins, or ART referral. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise hormonal profiling and reducing infertility-related distress. Its serum-based approach ensures reliable multi-hormone assessment.**Other Names**: Infert Female Pnl.**FDA Status**: FDA approved, CLIA certified for endocrinology/immunology, compliant with 2025 standards.**Historical Milestone**: Comprehensive female infertility panel standard; in India, used in ART centers.**Purpose**: The test assesses 7 parameters including FSH to guide female infertility evaluation, identify hormonal causes, inform ovulation induction/ART.**Test Parameters**: 1. FSH, 2. LH, 3. Prolactin, 4. AMH, 5. Estradiol, 6. Progesterone, 7. TSH.**Pretest Condition**: Fasting 10-12 hours recommended (day 2-5 of cycle for basal hormones); patients should report infertility or irregular cycles.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on cycle regularity, prior pregnancies, PCOS symptoms.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated infertility including prolonged distress, benefits of hormonal assessment, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or incorrect cycle day can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal levels (high FSH/low AMH) indicate diminished reserve; high prolactin/TSH suggest treatable causes, necessitating specialist input.**Specialist Consultation**: Reproductive endocrinologists or gynecologists should be consulted for management.**Additional Supporting Tests**: Pelvic ultrasound, HSG for confirmation.**Test Limitations**: Cycle-day dependent; comprehensive approach required.**References**: Indian Journal of Obstetrics and Gynaecology 2024, Infertility Studies India 2023. |
